FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297541629> ?p ?o ?g. }

• W4297541629 endingPage "5728" @default.
• W4297541629 startingPage "5728" @default.
• W4297541629 abstract "Patients with acute myocardial infarction are at high risk for developing heart failure due to scar development. Although regenerative approaches are evolving, consistent clinical benefits have not yet been reported. Treatment with dutogliptin, a second-generation DPP-4 inhibitor, in co-administration with filgrastim (G-CSF) has been shown to enhance endogenous repair mechanisms in experimental models. The REC-DUT-002 trial was a phase 2, multicenter, double-blind placebo-controlled trial which explored the safety, tolerability, and efficacy of dutogliptin and filgrastim in patients with ST-elevation Myocardial Infarction (STEMI). Patients (n = 47, 56.1 ± 10.7 years, 29% female) with STEMI, reduced left ventricular ejection fraction (EF ≤ 45%) and successful revascularization following primary PCI were randomized to receive either study treatment or matching placebo. Cardiac magnetic resonance imaging (cMRI) was performed within 72 h post-PCI and repeated after 3 months. The study was closed out early due to the SARS-CoV-2 pandemic. There was no statistically significant difference between the groups with respect to serious adverse events (SAE). Predefined mean changes within cMRI-derived functional and structural parameters from baseline to 90 days did not differ between placebo and treatment (left ventricular end-diastolic volume: +13.7 mL vs. +15.7 mL; LV-EF: +5.7% vs. +5.9%). Improvement in cardiac tissue health over time was noted in both groups: full-width at half-maximum late gadolinium enhancement (FWHM LGE) mass (placebo: −12.7 g, treatment: −19.9 g; p = 0.23). Concomitant treatment was well tolerated, and no safety issues were detected. Based on the results, the FDA and EMA have already approved an adequately powered large outcome trial." @default.
• W4297541629 created "2022-09-29" @default.
• W4297541629 creator A5009903680 @default.
• W4297541629 creator A5011401640 @default.
• W4297541629 creator A5012095697 @default.
• W4297541629 creator A5015803547 @default.
• W4297541629 creator A5039611814 @default.
• W4297541629 creator A5048249201 @default.
• W4297541629 creator A5051264655 @default.
• W4297541629 creator A5054043795 @default.
• W4297541629 creator A5055700473 @default.
• W4297541629 creator A5060727278 @default.
• W4297541629 creator A5066352672 @default.
• W4297541629 creator A5067935886 @default.
• W4297541629 creator A5071354446 @default.
• W4297541629 creator A5086692319 @default.
• W4297541629 creator A5091436608 @default.
• W4297541629 date "2022-09-27" @default.
• W4297541629 modified "2023-10-18" @default.
• W4297541629 title "Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction—The REC-DUT-002 Trial" @default.
• W4297541629 cites W1982861439 @default.
• W4297541629 cites W2007982994 @default.
• W4297541629 cites W2010653927 @default.
• W4297541629 cites W2020020716 @default.
• W4297541629 cites W2159254137 @default.
• W4297541629 cites W2182341201 @default.
• W4297541629 cites W2462121082 @default.
• W4297541629 cites W2543184578 @default.
• W4297541629 cites W2618612063 @default.
• W4297541629 cites W2737232808 @default.
• W4297541629 cites W2754054868 @default.
• W4297541629 cites W2773394667 @default.
• W4297541629 cites W2790350670 @default.
• W4297541629 cites W2792920533 @default.
• W4297541629 cites W2810098150 @default.
• W4297541629 cites W2947576810 @default.
• W4297541629 cites W3019645828 @default.
• W4297541629 cites W3047129023 @default.
• W4297541629 cites W3080510334 @default.
• W4297541629 cites W4205267468 @default.
• W4297541629 cites W4225761142 @default.
• W4297541629 doi "https://doi.org/10.3390/jcm11195728" @default.
• W4297541629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36233596" @default.
• W4297541629 hasPublicationYear "2022" @default.
• W4297541629 type Work @default.
• W4297541629 citedByCount "1" @default.
• W4297541629 crossrefType "journal-article" @default.
• W4297541629 hasAuthorship W4297541629A5009903680 @default.
• W4297541629 hasAuthorship W4297541629A5011401640 @default.
• W4297541629 hasAuthorship W4297541629A5012095697 @default.
• W4297541629 hasAuthorship W4297541629A5015803547 @default.
• W4297541629 hasAuthorship W4297541629A5039611814 @default.
• W4297541629 hasAuthorship W4297541629A5048249201 @default.
• W4297541629 hasAuthorship W4297541629A5051264655 @default.
• W4297541629 hasAuthorship W4297541629A5054043795 @default.
• W4297541629 hasAuthorship W4297541629A5055700473 @default.
• W4297541629 hasAuthorship W4297541629A5060727278 @default.
• W4297541629 hasAuthorship W4297541629A5066352672 @default.
• W4297541629 hasAuthorship W4297541629A5067935886 @default.
• W4297541629 hasAuthorship W4297541629A5071354446 @default.
• W4297541629 hasAuthorship W4297541629A5086692319 @default.
• W4297541629 hasAuthorship W4297541629A5091436608 @default.
• W4297541629 hasBestOaLocation W42975416291 @default.
• W4297541629 hasConcept C126322002 @default.
• W4297541629 hasConcept C142724271 @default.
• W4297541629 hasConcept C164705383 @default.
• W4297541629 hasConcept C197934379 @default.
• W4297541629 hasConcept C204787440 @default.
• W4297541629 hasConcept C27081682 @default.
• W4297541629 hasConcept C2776694085 @default.
• W4297541629 hasConcept C2777767877 @default.
• W4297541629 hasConcept C2777798775 @default.
• W4297541629 hasConcept C2778198053 @default.
• W4297541629 hasConcept C2778375690 @default.
• W4297541629 hasConcept C2779171977 @default.
• W4297541629 hasConcept C2779464278 @default.
• W4297541629 hasConcept C45393284 @default.
• W4297541629 hasConcept C500558357 @default.
• W4297541629 hasConcept C71924100 @default.
• W4297541629 hasConcept C78085059 @default.
• W4297541629 hasConceptScore W4297541629C126322002 @default.
• W4297541629 hasConceptScore W4297541629C142724271 @default.
• W4297541629 hasConceptScore W4297541629C164705383 @default.
• W4297541629 hasConceptScore W4297541629C197934379 @default.
• W4297541629 hasConceptScore W4297541629C204787440 @default.
• W4297541629 hasConceptScore W4297541629C27081682 @default.
• W4297541629 hasConceptScore W4297541629C2776694085 @default.
• W4297541629 hasConceptScore W4297541629C2777767877 @default.
• W4297541629 hasConceptScore W4297541629C2777798775 @default.
• W4297541629 hasConceptScore W4297541629C2778198053 @default.
• W4297541629 hasConceptScore W4297541629C2778375690 @default.
• W4297541629 hasConceptScore W4297541629C2779171977 @default.
• W4297541629 hasConceptScore W4297541629C2779464278 @default.
• W4297541629 hasConceptScore W4297541629C45393284 @default.
• W4297541629 hasConceptScore W4297541629C500558357 @default.
• W4297541629 hasConceptScore W4297541629C71924100 @default.
• W4297541629 hasConceptScore W4297541629C78085059 @default.
• W4297541629 hasIssue "19" @default.

• next